BioTime to Participate in the Jefferies 2017 London Healthcare Conference
BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, will participate in the Jefferies 2017 London Healthcare Conference on November 15th and 16th , in London, United Kingdom.
The Jefferies London Healthcare Conference is the largest healthcare-dedicated conference in Europe. There is expected to be over 350 participating companies from around the world. The two-day event will include concurrent tracks of company presentations, thematic panel discussions and 1x1/small-group meetings.
One-on-one meetings with Mr. Mohanty and/or Mr. Skibsted can be arranged by scheduling through the Jefferies 1x1 desk or by contacting David Nakasone, Director of Investor Relations at BioTime, at 510-871-4188 or firstname.lastname@example.org .
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells and cell/drug delivery. The foundation of BioTime’s core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of the Company’s cell delivery platform is its HyStem® cell and drug delivery matrix technology. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation, and a private company, AgeX Therapeutics.
BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter , LinkedIn , Facebook , YouTube , and Google+ .
To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
VERTEX-PHARMACEUTICALS19.10.2018 13:56 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
TX-SCHLUMBERGER-LIMITED19.10.2018 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results
CA-TRADESHIFT19.10.2018 13:02 | pressemeddelelse
Tradeshift Announces Q3 2018 Results
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum